US Organoids and Spheroids Market Size, Share, Trends, Industry Analysis Report: By Type (Organoids and Spheroids), Application, and End Use; Market Forecast, 2025-2034

Description

List of Tables

The US organoids and spheroids market size is expected to reach USD 2,488.22 million by 2034, according to a new study by Polaris Market Research. The report "US Organoids and Spheroids Market Size, Share, Trends, Industry Analysis Report: By Type (Organoids and Spheroids), Application, and End Use; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

An increasing number of biotechnology companies focused on therapeutic development and disease mechanism research drives the US organoids and spheroids market growth. As the prevalence of chronic health issues continues to rise across the country, there is a heightened need for innovative research methodologies to understand these conditions better. Organoids and spheroids provide valuable models for studying disease dynamics and testing potential treatments, fueling biotechnological research activities. Consequently, increasing research activities in the biotechnology segment is expected to boost the US organoids and spheroids market growth in the coming years.

Ongoing research into tissue models to better understand disease dynamics is expected to propel the growth of the US organoids and spheroids market significantly. The increasing incidence of abnormal organ development in infants highlights the urgent need for effective healthcare screening models. Approximately 30% of newborns with congenital diaphragmatic hernia are anticipated to face severe challenges, often resulting in prolonged hospital stays. This alarming statistic underscores the necessity for innovative disease detection methods, motivating researchers to develop advanced organoid and spheroid technologies that can enhance early diagnosis and treatment strategies.

The rising incidence of opioid use disorders is underscoring the critical role of spheroids in drug research and development. According to the World Drug Report 2023 by the United Nations Office on Drugs and Crime (UNODC), opioid consumption in India among individuals aged 10 to 75 ranges from 0.2% to 25.2%, with opioid disorders affecting ~0.1% to 6.9% of the population. This alarming trend is driving innovative research in drug discovery. A November 2023 study published in Communications Biology explored a brain-regional-specific model using spheroids to investigate neurological diseases, including opioid use disorders and Alzheimer's, enhancing therapeutic screening efforts.

US Organoids and Spheroids Market Report Highlights

By type, the spheroids segment is anticipated to witness a higher growth rate during the forecast period due to its potential to promote cell-to-cell interactions.

In terms of application, the developmental biology segment accounted for the largest market share in 2024, owing to the increasing research studies exploring cancer and neurodegenerative diseases.

Texas is projected to register the highest growth rate during 2025-2034, attributable to the rising research collaborations of the major companies.

3D Biotek, 3D Biomatrix, Aragen Bioscience, Cell Microsystems, Corning Incorporated, Danaher, Perkin Elmer, and Prellis Biologics are among the major market players.

Polaris Market Research has segmented the US organoids and spheroids market report on the basis of type, application, and end use:

By Type Outlook (Revenue - USD Million, 2020-2034)

Organoids
Type
Neural Organoids
Hepatic Organoids
Intestinal Organoids
Other
Method
General Submerged Method for Organoid Culture
Crypt Organoid Culture Techniques
Air Liquid Interface (ALI) Method for Organoid Culture
Clonal Organoids from Lgr5+ Cells
Brain and Retina Organoid Formation Protocol
Other
Source
Primary Tissues
Stem Cells
Spheroids
Type
Multicellular Tumor Spheroids (MCTS)
Neurospheres
Mammospheres
Hepatospheres
Embryoid Bodies
Method
Micropatterned Plates
Low Cell Attachment Plates
Hanging Drop Method
Others
Source
Cell Line
Primary Cell
iPSCs Derived Cells

By Application Outlook (Revenue - USD Million, 2020-2034)

Developmental Biology
Personalized Medicine
Regenerative Medicine
Disease Pathology Studies
Drug Toxicity & Efficacy Testing

By End User Outlook (Revenue - USD Billion, 2020-2034)

Biotechnology and Pharmaceutical Industries
Academic & Research Institutes
Hospitals and Diagnostic Centers

Product Code: PM5204

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. US Organoid and Spheroid Market Insights

4.1. US Organoid and Spheroid Market - End User Snapshot
4.2. US Organoid and Spheroid Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Rising Research on Chronic Disorders is Driving Market Growth
  - 4.2.1.2. Growing Adoption of Organoids and Spheroids in Genetic Disorder Drives Market Outlook
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Initial Investment\
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. US Organoid and Spheroid Market End User Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. US Organoid and Spheroid Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. US Organoid and Spheroid Market, by Type, 2020-2034 (USD Million)
5.3. Organoids
- 5.3.1. US Organoid and Spheroid Market, by Organoids, 2020-2034 (USD Million)
5.4. Spheroids

6. US Organoid and Spheroid Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. US Organoid and Spheroid Market, by Application, 2020-2034 (USD Million)
6.3. Developmental Biology
- 6.3.1. US Organoid and Spheroid Market, by Developmental Biology, 2020-2034 (USD Million)
6.4. Personalized Medicine
- 6.4.1. US Organoid and Spheroid Market, by Personalized Medicine, 2020-2034 (USD Million)
6.5. Regenerative Medicine
- 6.5.1. US Organoid and Spheroid Market, by Regenerative Medicine, 2020-2034 (USD Million)
6.6. Disease Pathology Studies
- 6.6.1. US Organoid and Spheroid Market, by Disease Pathology Studies, 2020-2034 (USD Million)
6.7. Drug Toxicity & Efficacy Testing
- 6.7.1. US Organoid and Spheroid Market, by Drug Toxicity & Efficacy Testing, 2020-2034 (USD Million)

7. US Organoid and Spheroid Market, by End User

7.1. Key Findings
7.2. Introduction
- 7.2.1. US Organoid and Spheroid Market, by End User, 2020-2034 (USD Million)
7.3. Biotechnology and pharmaceutical industries
- 7.3.1. US Organoid and Spheroid Market, by Biotechnology and pharmaceutical industries, 2020-2034 (USD Million)
7.4. Academic & Research Institutes
- 7.4.1. US Organoid and Spheroid Market, by Academic & Research Institutes, 2020-2034 (USD Million)
7.5. Hospitals and Diagnostic centers
- 7.5.1. US Organoid and Spheroid Market, by Hospitals and Diagnostic centers, 2020-2034 (USD Million)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. 3D Biotek LLC
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. 3D Biomatrix
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Aragen Bioscience
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Cell Microsystems
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Corning Incorporated
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Danaher
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. Perkin Elmer, Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Prellis Biologics
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Sigma-Aldrich Co. LLC
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Thermo Fisher Scientific, Inc
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development